Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
This activity is supported by educational grants from Apellis Pharmaceuticals, Inc., and Topcon Healthcare, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by educational grants from Apellis Pharmaceuticals, Inc., and Topcon Healthcare, Inc.
Activity Description
Multimodal imaging is key for the early detection and monitoring of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Optical coherence tomography has recently been recommended by an international consensus to be the primary imaging method for the detection of atrophy in eyes. Once diagnosed, timely therapeutic intervention should be initiated with recently FDA-approved therapies that target components of the complement cascade. When optimally integrated into personalized management protocols, these therapies have the potential to slow the growth rate of GA lesions and delay subsequent vision loss. In this CE monograph, experts in the field will review the most recent findings on the pathophysiology of GA secondary to AMD, assess the latest imaging tools for the detection and monitoring of disease progression, and evaluate the latest clinical evidence on approved therapies while providing practical approaches for optimal patient selection. Challenging real-world cases will also be presented, allowing for application of the content into clinical practice.
Target Audience
The intended audience for this activity is retina specialists, ophthalmologists, and other healthcare professionals involved in the management of patients with or at risk for GA secondary to AMD.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Understand the most recent findings on the pathophysiology of GA secondary to AMD as well as the detection and monitoring of disease progression using the latest imaging tools.
- Apply the latest clinical evidence and practical approaches for differentiating the newly approved therapies for GA secondary to AMD that can aid in selecting patients who may benefit from them.
Activity Chair
Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH
Faculty
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Medical Writer
Valerie Zimmerman, PhD
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 31, 2024, to August 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
The articles in this monograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Regillo and Singh during a satellite symposium held on May 11, 2024. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Carl D. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Alcon, Allergan, Annexon, Apellis, Aviceda, Clearside, Cognition Therapeutics, EyePoint, Genentech, Graybug, IVERIC bio, Janssen, Kodiak, Lineage Cell Therapeutics, Merck, NGM Bio, Novartis, Ocugen, Ocuphire, OcuTerra, Opthea, Ray, Regeneron, Regenxbio, Stealth BioTherapeutics, Théa, Zeiss
Independent Research Contractor: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Graybug, Gyroscope, IVERIC bio, Kodiak, Lineage Cell Therapeutics, NGM Bio, Notal Vision, Novartis, Ocugen, Opthea, Regeneron, Regenxbio
Rishi P. Singh, MD
Consultant: Alcon, Apellis, Aviceda, Bausch + Lomb, EyePoint, Genentech, IVERIC bio, Regeneron
Medical Writer reports the following relevant financial relationship(s)
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com